首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   743483篇
  免费   54181篇
  国内免费   3958篇
耳鼻咽喉   9454篇
儿科学   23759篇
妇产科学   18051篇
基础医学   114970篇
口腔科学   20767篇
临床医学   68813篇
内科学   139749篇
皮肤病学   16580篇
神经病学   51203篇
特种医学   27157篇
外国民族医学   93篇
外科学   108606篇
综合类   21646篇
现状与发展   14篇
一般理论   175篇
预防医学   54144篇
眼科学   17612篇
药学   57814篇
  60篇
中国医学   4721篇
肿瘤学   46234篇
  2021年   7731篇
  2019年   6885篇
  2018年   9343篇
  2017年   7449篇
  2016年   8069篇
  2015年   9442篇
  2014年   12634篇
  2013年   17578篇
  2012年   23545篇
  2011年   24842篇
  2010年   14866篇
  2009年   13734篇
  2008年   22156篇
  2007年   23611篇
  2006年   24026篇
  2005年   22248篇
  2004年   21294篇
  2003年   20073篇
  2002年   19394篇
  2001年   37129篇
  2000年   37660篇
  1999年   31167篇
  1998年   8387篇
  1997年   7128篇
  1996年   7333篇
  1995年   6943篇
  1994年   6417篇
  1992年   23192篇
  1991年   23104篇
  1990年   22455篇
  1989年   22259篇
  1988年   20159篇
  1987年   19540篇
  1986年   18525篇
  1985年   17370篇
  1984年   12741篇
  1983年   10770篇
  1982年   5945篇
  1979年   11543篇
  1978年   8138篇
  1977年   6837篇
  1976年   6597篇
  1975年   7277篇
  1974年   8508篇
  1973年   8144篇
  1972年   7660篇
  1971年   7127篇
  1970年   6878篇
  1969年   6308篇
  1968年   5780篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
中医学古籍中罕有关于“胰腺”的明确记载,缺乏直观、系统的理论论述。本文试图通过对各个时期具有代表性的医学典籍所记载内容的分析,结合现代解剖学相关理论,梳理中医学对胰腺实体解剖的认识过程。通过分析,笔者认为中医学对胰腺实体解剖的认识具有阶段性:①先秦两汉时期,存在胰腺实体解剖,但并非认为胰腺是脏器;②唐宋时期,胰腺实体解剖更加清晰,在医学上胰腺附属于脾,并非为独立的脏器;③明清时期,胰腺实体解剖明确,部分医家以独立脏器论之,出现“脾”、“胰”之争。中医学理论缺少对胰腺的单独论述,目前学界的主流观点多为“胰属脾”,线性归属以脾笼统代之略显单薄,不利于理论的丰富与发展。笔者认为胰腺藏象应独立于脾单独讨论,现代解剖学对胰腺命名同一,形态结构清楚,位置描述明确,可直接补充进中医学胰腺藏象(藏)理论中,为完善胰腺藏象理论搭建解剖学基础。  相似文献   
2.

Interstitial lung disease (ILD) represents a significant cause of morbidity and mortality in systemic sclerosis (SSc). The purpose of this study was to examine recirculating lymphocytes from SSc patients for potential biomarkers of interstitial lung disease (ILD). Peripheral blood mononuclear cells (PBMCs) were isolated from patients with SSc and healthy controls enrolled in the Vanderbilt University Myositis and Scleroderma Treatment Initiative Center cohort between 9/2017–6/2019. Clinical phenotyping was performed by chart abstraction. Immunophenotyping was performed using both mass cytometry and fluorescence cytometry combined with t-distributed stochastic neighbor embedding analysis and traditional biaxial gating. This study included 34 patients with SSc-ILD, 14 patients without SSc-ILD, and 25 healthy controls. CD21lo/neg cells are significantly increased in SSc-ILD but not in SSc without ILD (15.4 ± 13.3% vs. 5.8 ± 0.9%, p = 0.002) or healthy controls (5.0 ± 0.5%, p < 0.0001). While CD21lo/neg B cells can be identified from a single biaxial gate, tSNE analysis reveals that the biaxial gate is comprised of multiple distinct subsets, all of which are increased in SSc-ILD. CD21lo/neg cells in both healthy controls and SSc-ILD are predominantly tBET positive and do not have intracellular CD21. Immunohistochemistry staining demonstrated that CD21lo/neg B cells diffusely infiltrate the lung parenchyma of an SSc-ILD patient. Additional work is needed to validate this biomarker in larger cohorts and longitudinal studies and to understand the role of these cells in SSc-ILD.

  相似文献   
3.
4.
5.
6.
The coronavirus disease 2019 (COVID-19) pandemic has rapidly created widespread impacts on global health and the economy. Data suggest that women are less susceptible to severe illness. However, sex-disaggregated data are incomplete, leaving room for misinterpretation, and focusing only on biologic sex underestimates the gendered impact of the pandemic on women. This narrative review summarizes what is known about gender disparities during the COVID-19 pandemic and the economic, domestic, and health burdens along with overlapping vulnerabilities related to the pandemic. In addition, this review outlines recommended strategies that advocacy groups, community leaders, and policymakers should implement to mitigate the widening gender disparities related to COVID-19.  相似文献   
7.
IntroductionHip displacement is common in cerebral palsy (CP) and is related to the severity of neurological and functional impairment. It is a silent, but progressive disease, and can result in significant morbidity and decreased quality of life, if left untreated. The pathophysiology of hip displacement in CP is a combination of hip flexor-adductor muscle spasticity, abductor muscle weakness, and delayed weight-bearing, resulting in proximal femoral deformities and progressive acetabular dysplasia. Due to a lack of symptoms in the early stages of hip displacement, the diagnosis is easily missed. Awareness of this condition and regular surveillance by clinical examination and serial radiographs of the hips are the key to early diagnosis and treatment.Hip surveillance programmesSeveral population-based studies from around the world have demonstrated that universal hip surveillance in children with CP allows early detection of hip displacement and appropriate early intervention, with a resultant decrease in painful dislocations. Global hip surveillance models are based upon the patients’ age, functional level determined by the Gross Motor Function Classification system (GMFCS), gait classification, standardized clinical exam, and radiographic indices such as the migration percentage (MP), as critical indicators of progressive hip displacement.ConclusionDespite 25 years of evidence showing the efficacy of established hip surveillance programmes, there is poor awareness among healthcare professionals in India about the importance of regular hip surveillance in children with CP. There is a need for professional organizations to develop evidence-based guidelines for hip surveillance which are relevant to the Indian context.  相似文献   
8.
Inflammatory bowel disease (IBD) is a chronic disease that requires chronic treatment throughout the evolution of the disease, with a complex physiopathology that entails great challenges for the development of new and specific treatments for ulcerative colitis and Crohn´s disease. The anti-tumor necrosis factor alpha therapy has impacted the clinical course of IBD in those patients who do not respond to conventional treatment, so there is a need to develop new therapies and markers of treatment response. Various pathways involved in the development of the disease are known and the new therapies have focused on blocking the inflammatory process at the gastrointestinal level by oral, intravenous, subcutaneous, and topical route. All these new therapies can lead to more personalized treatments with higher success rates and fewer relapses. These treatments have not only focused on clinical remission, but also on achieving macroscopic changes at the endoscopic level and microscopic changes by achieving mucosal healing. These treatments are mainly based on modifying signaling pathways, by blocking receptors or ligands, reducing cell migration and maintaining the integrity of the epithelial barrier. Therefore, this review presents the efficacy and safety of the new treatments that are currently under study and the advances that have been made in this area in recent years.  相似文献   
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号